NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on May 08, 2023. Total no. of equity shares bought back are 650000 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on May 04, 2023. Total no. of equity shares bought back are 8350 NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of Duplicate Share Certificates NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on May 02, 2023. Total no. of equity shares bought back are 0 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on April 26, 2023. Total no. of equity shares bought back are 8800 NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on April 24, 2023. Total no. of equity shares bought back are 8700 NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares
Daily report pursuant to Regulation 18(i) of the Buyback Regulations regarding the equity shares bought-back on April 21, 2023. Total no. of equity shares bought back are 0
Natco Pharma to set up subsidiary in Indonesia with investment of $3 mn
Natco Pharma Ltd on Thursday said its board has approved setting up of a subsidiary in Indonesia with an investment of up to USD 3 million (nearly Rs 25 crore) for selling pharmaceutical products in that country. The new subsidiary -- PT. NATCO Lotus Farma -- will be a joint venture with Natco holding 51 per cent and the balance stake 49 per cent by PT. Mitra Medis Exim (MME), a part of Mitra Jaya Group, which is a 40 year old multi-diversified group, as the co-promoter, the company said in a regulatory filing. The company's board approved the proposal at its meeting held on Thursday. Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added. PT. NATCO Lotus Farma will be engaged in selling pharmaceutical products in Indonesia, it added. MME is in the business of distribution for active pharmaceutical ingredients and excipients for end-users in Indonesia. NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of Board Meeting
The Board of Directors have approved to incorporate a Subsidiary Company in Indonesia with an investment up to an amount not exceeding US$ 3 Million (Three Million United States Dollars only), of which, initially the Company will invest US$ 1 Million (One Million United States Dollars only) for a stake of 51% (Fifty One Percent) as capital contribution and balance will be invested by the Company as and when the funds are required by the subsidiary Company. The balance stake of 49% (Forty Nine Percent) will be held by PT. Mitra Medis Exim (MME), that belongs to Mitra Jaya Group which is a 40 year old multi-diversified group, as the co-promoter of the proposed subsidiary Company. MME is in the business of distribution for active pharmaceutical ingredients and excipients for the end users in Indonesia.